Is Caidya profitable in 2026?

Caidya does not disclose audited financials. Third-party data brokers like Datanyze estimate annual revenue around $300 to 365 million as of 2026, but no profitability figures have been publicly confirmed by the company itself.

Caidya is privately held, tracing ownership to dMedClinical Co. Ltd. with investors in the People's Republic of China, alongside Rubicon Founders which put in a $165 million growth investment in January 2025, per Caidya's own announcement.

Who is Caidya's biggest competitor?

Caidya competes against mid-tier peers like Medpace, Fortrea, and Worldwide Clinical Research, and faces much larger incumbents including IQVIA at $14.5 billion 2024 revenue and ICON at $8.2 billion, per Towards Healthcare data from 2024.

Could AI replace Caidya's clinical trial work?

AI is reshaping protocol design and feasibility modeling industry-wide, and in February 2026 AI-agent fears triggered a CRO stock sell-off that cost IQVIA about $7.3 billion in market cap, per Salesmotion reporting, but regulated trial execution and liability remain resistant to automation.

What is Caidya's revenue?

No audited figure has been disclosed. Data broker Datanyze estimates roughly $365.2 million and Prospeo estimates around $300 million as of 2026, both unconfirmed third-party estimates rather than company-reported figures.

Is Caidya linked to China?

Yes. Caidya's ownership traces to dMedClinical Co. Ltd., disclosed by the company itself as having investors located in the People's Republic of China, per Caidya's 2022 name-change announcement covering the dMed-Clinipace merger history.

United States · subsidiary of dMedClinical Co. Ltd. (via merger 2021; rebranded 2022; Simbec-Orion absorbed June 2026) · United States

Caidya

Mid-tier CRO running clinical trials for biopharma, born from a dMed-Clinipace merger.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from late 2026 · Every call on the record Checkpoint: Simbec-Orion integration outcome, bookings, margins, and headcount stability

The call

Caidya is a real, revenue-generating CRO mid-integration with Simbec-Orion, sitting in a crowded lane between AI-armed giants and its own unresolved ownership questions.

Caidya runs clinical trials for pharmaceutical companies, earning about $300-365 million per year. The company is hard to replace quickly because drug trials require government approval and face strict safety rules that AI cannot yet handle alone, but it competes in a crowded middle tier against larger players like IQVIA (14 times bigger) that have better technology, more data, and deeper pockets. The key wildcard is whether Caidya can smoothly combine its recent purchase of Simbec-Orion, keep its team stable, and hold onto customers as the big rivals roll out AI tools to steal work from smaller competitors.

Why

AI pressure: AI agents from labs like Anthropic and IQVIA's AI Commercial Suite. AI can already draft protocols and pick trial sites, but regulated trial execution still needs licensed humans signing off. Could AI do the core job? Only partly.

Bigger players: IQVIA, ICON, Thermo Fisher/PPD, WuXi AppTec. These giants already run AI-assisted trial platforms at massive scale, squeezing mid-tier CROs like Caidya on price and speed. Could a giant copy it? Yes, easily.

What protects it. Running clinical trials requires regulatory sign-off and liability that AI cannot assume, so human-run CROs stay necessary.

What would change this call

Caidya's disclosed headcount on its own site rises back toward ~1,800 or stays near ~1,130 through 2026. Shows whether the Simbec-Orion integration stabilized staffing or reflects ongoing contraction.
Public disclosure or regulatory action addressing Caidya's PRC-linked ownership chain. Would show whether the geopolitical ownership risk resolves cleanly or triggers sponsor/client caution.
Caidya announces a named, differentiated AI or tech product for trial design, site selection, or feasibility modeling. Would show whether it can defend against IQVIA/ICON AI tooling pulling mid-tier RFPs away.

Key numbers

$165M growth investment from Rubicon Founders (2025-01)
Combined with Simbec-Orion in strategic deal (2026-06-30)
3,800 principal investigators, 2,700 site relationships (2026-06)

Named risks

Unexplained headcount drop from ~1,800 to 1,130+ employees between 2022-2025 and mid-2026. Severity: high
PRC-linked ownership via dMedClinical Co. Ltd. faces potential US-China regulatory scrutiny. Severity: high
Simbec-Orion combination is a leveraged buyout mid-integration, adding debt load and execution risk through late 2026. Severity: medium
Crowded mid-tier CRO lane against Medpace, Fortrea, and Worldwide Clinical Research with no proprietary tech moat. Severity: medium
No named AI product versus IQVIA's AI Commercial Suite and Azure partnership, risking RFP loss to mega-CROs. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
IQVIA	losing to	IQVIA generated $14.5B revenue in 2024 with an AI Commercial Suite versus Caidya's ~$300-365M estimated revenue
ICON plc	contesting	Named as a direct competitor by Pitchbook in 2026, ICON reported $8.2B revenue in 2024
Medpace	losing to	Medpace reported materially larger and more profitable full-year 2025 results per its Feb 2026 earnings release
Fortrea	contesting	Named mid-tier peer competing for same small-to-mid biotech clientele as of 2026

Questions people ask

Is Caidya profitable in 2026?: Caidya does not disclose audited financials. Third-party data brokers like Datanyze estimate annual revenue around $300 to 365 million as of 2026, but no profitability figures have been publicly confirmed by the company itself.
Who owns Caidya?: Caidya is privately held, tracing ownership to dMedClinical Co. Ltd. with investors in the People's Republic of China, alongside Rubicon Founders which put in a $165 million growth investment in January 2025, per Caidya's own announcement.
Who is Caidya's biggest competitor?: Caidya competes against mid-tier peers like Medpace, Fortrea, and Worldwide Clinical Research, and faces much larger incumbents including IQVIA at $14.5 billion 2024 revenue and ICON at $8.2 billion, per Towards Healthcare data from 2024.
Could AI replace Caidya's clinical trial work?: AI is reshaping protocol design and feasibility modeling industry-wide, and in February 2026 AI-agent fears triggered a CRO stock sell-off that cost IQVIA about $7.3 billion in market cap, per Salesmotion reporting, but regulated trial execution and liability remain resistant to automation.
What is Caidya's revenue?: No audited figure has been disclosed. Data broker Datanyze estimates roughly $365.2 million and Prospeo estimates around $300 million as of 2026, both unconfirmed third-party estimates rather than company-reported figures.
Is Caidya linked to China?: Yes. Caidya's ownership traces to dMedClinical Co. Ltd., disclosed by the company itself as having investors located in the People's Republic of China, per Caidya's 2022 name-change announcement covering the dMed-Clinipace merger history.

Timeline

2026-06-30Caidya announces strategic combination with UK-based Simbec-Orion, logged by Pitchbook as a Buyout/LBO
2026-06-08Caidya's own contact page lists 1,130+ employees across 50+ countries, down from prior 1,800 figure
2025-01Caidya announces $165 million strategic growth investment from Rubicon Founders
2024Barbara Lopez Kunz appointed CEO, prior CEO of the Drug Information Association
2022Company rebrands from dMed-Clinipace to Caidya
2021Caidya formed via merger of China-founded dMed and US-founded Clinipace

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.